Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

26.58USD
13 Dec 2017
Change (% chg)

$0.58 (+2.23%)
Prev Close
$26.00
Open
$26.11
Day's High
$26.93
Day's Low
$25.74
Volume
152,677
Avg. Vol
67,587
52-wk High
$26.93
52-wk Low
$7.14

Chart for

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $347.34
Shares Outstanding(Mil.): 22.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update

Nov 09 2017

BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

Nov 06 2017

BRIEF-Concert Pharma pays total of $30.8 mln to Hercules Capital

* Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8

Sep 08 2017

BRIEF-Concert Pharmaceuticals reports Q2 loss per share $0.58

* Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update

Aug 08 2017

BRIEF-Vertex and Concert Pharmaceuticals complete asset purchase agreement

* Vertex and Concert Pharmaceuticals complete asset purchase agreement for CTP-656 Source text for Eikon: Further company coverage:

Jul 25 2017

BRIEF-Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement

* Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex

Jul 24 2017

FDA lifts hold on Concert Pharma's study testing hair loss drug

Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.

Jul 10 2017

UPDATE 1-FDA lifts hold on Concert Pharma's study testing hair loss drug

July 10 Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) lifted a clinical hold on a trial testing its therapy for alopecia areata, a type of hair loss.

Jul 10 2017

BRIEF-Concert Pharma says FDA lifts clinical hold on its clinical trial with CTP-543

* Fda lifts clinical hold on concert pharmaceuticals clinical trial with ctp-543

Jul 10 2017

FDA lifts hold on Concert Pharma's hair loss drug

July 10 Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.

Jul 10 2017

Earnings vs. Estimates